BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 21387309)

  • 1. Oct1 regulates cell growth of LNCaP cells and is a prognostic factor for prostate cancer.
    Obinata D; Takayama K; Urano T; Murata T; Kumagai J; Fujimura T; Ikeda K; Horie-Inoue K; Homma Y; Ouchi Y; Takahashi S; Inoue S
    Int J Cancer; 2012 Mar; 130(5):1021-8. PubMed ID: 21387309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Oct1 genomic function inhibits androgen receptor signaling and castration-resistant prostate cancer growth.
    Obinata D; Takayama K; Fujiwara K; Suzuki T; Tsutsumi S; Fukuda N; Nagase H; Fujimura T; Urano T; Homma Y; Aburatani H; Takahashi S; Inoue S
    Oncogene; 2016 Dec; 35(49):6350-6358. PubMed ID: 27270436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of AR-mediated transcription by binding of Oct1 to a motif enriched in AR-occupied regions.
    Jariwala U; Cogan JP; Jia L; Frenkel B; Coetzee GA
    Prostate; 2009 Mar; 69(4):392-400. PubMed ID: 19058140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrative Genomic Analysis of OCT1 Reveals Coordinated Regulation of Androgen Receptor in Advanced Prostate Cancer.
    Takayama KI; Suzuki Y; Yamamoto S; Obinata D; Takahashi S; Inoue S
    Endocrinology; 2019 Feb; 160(2):463-472. PubMed ID: 30649323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of new octamer transcription factor 1-target genes upregulated in castration-resistant prostate cancer.
    Yamamoto S; Takayama KI; Obinata D; Fujiwara K; Ashikari D; Takahashi S; Inoue S
    Cancer Sci; 2019 Nov; 110(11):3476-3485. PubMed ID: 31454442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abhydrolase domain containing 2, an androgen target gene, promotes prostate cancer cell proliferation and migration.
    Obinata D; Takada S; Takayama K; Urano T; Ito A; Ashikari D; Fujiwara K; Yamada Y; Murata T; Kumagai J; Fujimura T; Ikeda K; Horie-Inoue K; Homma Y; Takahashi S; Inoue S
    Eur J Cancer; 2016 Apr; 57():39-49. PubMed ID: 26854828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. OCT1 Is a Poor Prognostic Factor for Breast Cancer Patients and Promotes Cell Proliferation via Inducing NCAPH.
    Ogura T; Azuma K; Sato J; Kinowaki K; Takayama KI; Takeiwa T; Kawabata H; Inoue S
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prostate cancer-up-regulated long noncoding RNA PlncRNA-1 modulates apoptosis and proliferation through reciprocal regulation of androgen receptor.
    Cui Z; Ren S; Lu J; Wang F; Xu W; Sun Y; Wei M; Chen J; Gao X; Xu C; Mao JH; Sun Y
    Urol Oncol; 2013 Oct; 31(7):1117-23. PubMed ID: 22264502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of androgen and estrogen signaling components and stem cell markers to predict cancer progression and cancer-specific survival in patients with metastatic prostate cancer.
    Fujimura T; Takahashi S; Urano T; Takayama K; Sugihara T; Obinata D; Yamada Y; Kumagai J; Kume H; Ouchi Y; Inoue S; Homma Y
    Clin Cancer Res; 2014 Sep; 20(17):4625-35. PubMed ID: 24987058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of androgen receptor expression by dibenzoylmethane as a therapeutic objective in advanced prostate cancer.
    Jackson KM; Frazier MC; Harris WB
    Anticancer Res; 2007; 27(3B):1483-8. PubMed ID: 17595765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells.
    Hååg P; Bektic J; Bartsch G; Klocker H; Eder IE
    J Steroid Biochem Mol Biol; 2005 Aug; 96(3-4):251-8. PubMed ID: 15982869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carbidopa abrogates L-dopa decarboxylase coactivation of the androgen receptor and delays prostate tumor progression.
    Wafa LA; Cheng H; Plaa N; Ghaidi F; Fukumoto T; Fazli L; Gleave ME; Cox ME; Rennie PS
    Int J Cancer; 2012 Jun; 130(12):2835-44. PubMed ID: 21780103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
    Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
    J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
    Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B
    Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate cancer: prognostic significance of the association of heterogeneous nuclear ribonucleoprotein K and androgen receptor expression.
    Barboro P; Salvi S; Rubagotti A; Boccardo S; Spina B; Truini M; Carmignani G; Introini C; Ferrari N; Boccardo F; Balbi C
    Int J Oncol; 2014 May; 44(5):1589-98. PubMed ID: 24626777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells.
    Weiss-Messer E; Merom O; Adi A; Karry R; Bidosee M; Ber R; Kaploun A; Stein A; Barkey RJ
    Mol Cell Endocrinol; 2004 May; 220(1-2):109-23. PubMed ID: 15196705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A gene signature identified using a mouse model of androgen receptor-dependent prostate cancer predicts biochemical relapse in human disease.
    Thompson VC; Day TK; Bianco-Miotto T; Selth LA; Han G; Thomas M; Buchanan G; Scher HI; Nelson CC; ; Greenberg NM; Butler LM; Tilley WD
    Int J Cancer; 2012 Aug; 131(3):662-72. PubMed ID: 22275114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential posttranscriptional regulation of androgen receptor gene expression by androgen in prostate and breast cancer cells.
    Yeap BB; Krueger RG; Leedman PJ
    Endocrinology; 1999 Jul; 140(7):3282-91. PubMed ID: 10385425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OCT1-target neural gene PFN2 promotes tumor growth in androgen receptor-negative prostate cancer.
    Obinata D; Funakoshi D; Takayama K; Hara M; Niranjan B; Teng L; Lawrence MG; Taylor RA; Risbridger GP; Suzuki Y; Takahashi S; Inoue S
    Sci Rep; 2022 Apr; 12(1):6094. PubMed ID: 35413990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.
    Yepuru M; Wu Z; Kulkarni A; Yin F; Barrett CM; Kim J; Steiner MS; Miller DD; Dalton JT; Narayanan R
    Clin Cancer Res; 2013 Oct; 19(20):5613-25. PubMed ID: 23995860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.